Literature DB >> 11451568

Intracellular and extracellular control of activin function by novel regulatory molecules.

K Tsuchida1, T Matsuzaki, N Yamakawa, Z Liu, H Sugino.   

Abstract

Activin signal transduction is regulated through multiple mechanisms. We have identified novel regulatory proteins that control activin functions either intracellularly or extracellularly. As intracellular molecules, PSD-95/Dlg/ZO-1 (PDZ) proteins that specifically associate with activin type II receptors (ActRIIs) were identified. We have named the molecules as activin receptor-interacting proteins (ARIPs). ARIP1 has two WW domains and five PDZ domains, associates not only with ActRIIs but also with Smads, and controls activin functions intracellularly in neuronal cells. Another ARIP we have found has only one PDZ domain, and is likely to be involved in intracellular trafficking and sorting of activin receptor complexes in the cell. As an extracellular regulatory protein, we have identified a novel follistatin-like protein, named follistatin-related gene (FLRG). Like follistatins, FLRG binds activins and bone morphogenetic proteins (BMPs) and controls their functions extracellularly. The mode of association of follistatin and FLRG with activins and their expression patterns are different, suggesting the distinct functions of follistatin and FLRG in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11451568     DOI: 10.1016/s0303-7207(01)00522-6

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  8 in total

Review 1.  Emerging roles for the transforming growth factor-{beta} superfamily in regulating adiposity and energy expenditure.

Authors:  Nader Zamani; Chester W Brown
Journal:  Endocr Rev       Date:  2010-12-20       Impact factor: 19.871

Review 2.  Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies.

Authors:  Mohammad Hassan Baig; Khurshid Ahmad; Jun Sung Moon; So-Young Park; Jeong Ho Lim; Hee Jin Chun; Afsha Fatima Qadri; Ye Chan Hwang; Arif Tasleem Jan; Syed Sayeed Ahmad; Shahid Ali; Sibhghatulla Shaikh; Eun Ju Lee; Inho Choi
Journal:  Front Physiol       Date:  2022-06-23       Impact factor: 4.755

3.  Human placenta and fetal membranes express follistatin-related gene mRNA and protein.

Authors:  P Ciarmela; P Florio; P Toti; A Franchini; V Maguer-Satta; C Ginanneschi; E Ottaviani; F Petraglia
Journal:  J Endocrinol Invest       Date:  2003-07       Impact factor: 4.256

4.  Tomoregulin-1 (TMEFF1) inhibits nodal signaling through direct binding to the nodal coreceptor Cripto.

Authors:  Paul W Harms; Chenbei Chang
Journal:  Genes Dev       Date:  2003-10-16       Impact factor: 11.361

5.  Regulation of activin receptor-interacting protein 2 expression in mouse hepatoma Hepa1-6 cells and its relationship with collagen type IV.

Authors:  Hong-Jun Zhang; Gui-Xiang Tai; Jing Zhou; Di Ma; Zhong-Hui Liu
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

6.  Expression and anti-inflammatory role of activin receptor-interacting protein 2 in lipopolysaccharide-activated macrophages.

Authors:  Qian Wu; Yan Qi; Na Wu; Chunhui Ma; Wenfang Feng; Xueling Cui; Zhonghui Liu
Journal:  Sci Rep       Date:  2017-09-04       Impact factor: 4.379

7.  Follistatin-Like 3 Enhances the Function of Endothelial Cells Derived from Pluripotent Stem Cells by Facilitating β-Catenin Nuclear Translocation Through Inhibition of Glycogen Synthase Kinase-3β Activity.

Authors:  Sophia Kelaini; Marta Vilà-González; Rachel Caines; David Campbell; Magdalini Eleftheriadou; Marianna Tsifaki; Corey Magee; Amy Cochrane; Karla O'neill; Chunbo Yang; Alan W Stitt; Lingfang Zeng; David J Grieve; Andriana Margariti
Journal:  Stem Cells       Date:  2018-04-10       Impact factor: 6.277

Review 8.  Perspectives of small molecule inhibitors of activin receptor‑like kinase in anti‑tumor treatment and stem cell differentiation (Review).

Authors:  Xueling Cui; Shumi Shang; Xinran Lv; Jing Zhao; Yan Qi; Zhonghui Liu
Journal:  Mol Med Rep       Date:  2019-04-30       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.